Madrigal Pharmaceuticals Inc
Closed
SectorHealthcare
533.54 1.74
Overview
Share price change
24h
Min
518.66
Max
542.85
Income | 36M -58M |
|---|---|
Sales | 53M 364M |
EPS | -1.99 |
Profit margin | -15.906 |
Employees | 915 |
EBITDA | 30M -56M |
Next Earnings | 3 lis 2026 |
|---|
Market Cap | -208M 13B |
|---|---|
Previous open | 531.8 |
Previous close | 533.54 |
News Sentiment
By Acuity
22%
78%
43 / 339 Ranking in Healthcare
Madrigal Pharmaceuticals Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Madrigal Pharmaceuticals Inc Forecast
Sentiment
By Acuity
43 / 339 Ranking in Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.